TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~The most important criteria for patient eligibility include:~1. Age \>=18 years~2. Patients must have received prior therapy (any number of therapies) for WM and have relapsed or refractory WM~3. Eastern Cooperative Oncology Group performance score of 0 - 2~4. Hemoglobin \>= 10g/dL or hematocrit \>= 30%~5. Absolute neutrophil count (ANC) \>1000/mm3 and platelet count \>75,000/mm3~6. Adequate organ function defined as~   * serum glutamate pyruvate transaminase and serum glutamate oxaloacetate transaminase \< 2 x International Unit/l~  * Total bilirubin \>= 1.5 mg/dL~  * Clearance creatinin \> 50 ml/mn~7. Evaluable immunochemical abnormalities including abnormal electrophoresis and serum free light chain assay with an increase of either kappa or lambda light chain lev -~Exclusion Criteria:~Key Exclusion criteria~1. Any other uncontrolled medical condition or comorbidity that might interfere with subject's participation~2. Patients treated or requiring corticosteroids \>30mg/day~3. Pregnant or breast feeding females (Lactating females must agree not to breast feed while taking lenalidomide)~4. Use of any other experimental drug or therapy within 28 days of baseline~5. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs~6. Known positive for HIV or infectious hepatitis, type A, B or C -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- revlimid (Type: OTHER): a dose-escalation of revlimid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients must have previously untreated MDS, AML, or CMML according to the WHO 2016 classification.~* MDS patients must have Intermediate (\>3 to 4.5 points), High Risk (\>4.5 - 6) or Very High Risk (\>6 points) disease according to the Revised International Prognostic Scoring System 2012 (IPSS-R).~* Clinical indication for treatment with azacitidine for MDS or AML.~Exclusion criteria:~* Patients with AML who are candidates for standard induction chemotherapy as first line treatment.~* Patients with known active CNS leukemia.~* Prior treatment with a smoothened inhibitor (SMOi) and/or hypomethylating agent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): MDS patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
- Arm B (Type: EXPERIMENTAL): AML patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with functional dyspepsia or peptic ulcers~* Subjects between the ages of 19 and 70 years old~* Subjects who were referred for upper endoscopy, and had not received previous H. pylori eradication treatment within the last six months.~* Subjects who had not received anti-secreting acid, bismuth or antibiotics for other diseases 15 days before the endoscopy.~* For the study, only patients with sensitive isolates of H.pylori to amoxicillin and clarithromycin were included.~Exclusion Criteria:~* Patients with serious comorbidities.~* Pregnant women.~* Patients allergic to the medications used in this study.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- amoxicillin clarithromycin omeprazole 1 (Type: EXPERIMENTAL): This group received triple standard therapy with standard doses of omeprazole. 20 mg omeprazole before breakfast and before dinner. 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days.
- amoxicillin clarithromycin omeprazole 2 (Type: EXPERIMENTAL): This group received triple standard therapy, using 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days in addition with omeprazole but omeprazole doses were prescribed according to CYP2C19 genotype as a follows: a) Patients with CYP2C19 \*1/\*1 genotype (Early and ultrarapid Metabolizer): 40mg omeprazole before breakfast and before dinner. b) Patients with CYP2C19 \*1/\*2 or \*1/\*3 genotype (Intermediate Metabolizer): 20mg omeprazole before breakfast, 20mg before lunch and 20mg before dinner. c) Patients with CYP2C19 \*2/\*2 (Poor Metabolizer): 20mg omeprazole before breakfast and 20 mg before dinner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus.~* Cardiovascular disease~* Hypertension~Exclusion Criteria:~* Patients with type 1 diabetes or diabetes insipidus~* Patients with 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or poorly controlled diabetes~* Any clinically significant illness, which would compromise the patient's safety and their participation in the study

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Dapagliflozin 10 mg tablet
- 2 (Type: PLACEBO_COMPARATOR): Matching placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting to the emergency department with a presumed diagnosis of mild to moderate skin and soft tissue infection~* Deemed well enough to be treated as an outpatient~* 19 years of age or older~Exclusion Criteria:~* known allergy to study drugs~* known chronic kidney disease with a creatinine clearance \<30 mL/min~* known previous methicillin-resistant staphylococcus aureus (MRSA) infection~* use of antibiotics for greater than 24 hours in the past 7 days~* wound/abscess requiring operative debridement or incision and drainage~* suspected necrotizing fasciitis, osteomyelitis or septic arthritis~* febrile neutropenia~* concomitant documented bacteremia~* Two or more signs of systemic sepsis~* new altered mental status~* infections at a site involving prosthetic materials~* animal or human bite wound infections~* post-operative wound infections~* known peripheral vascular disease~* superficial thrombophlebitis~* pregnant/breastfeeding~* obesity (BMI \> 30 kg/m2)

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV cefazolin plus oral probenecid and placebo cephalexin (Type: ACTIVE_COMPARATOR): None
- Oral cephalexin and saline IV plus probenecid placebo (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able and willing to give consent~* Women of childbearing potential must have a) negative urine pregnancy test b) not be breast feeding c) agree to practice a reliable form of contraception~* Diagnosis of cancer~* Taking at least 60mg oral morphine or equivalent as 24 hour treatment for cancer-related pain~* Experiencing on average 1 - 4 episodes of breakthrough cancer pain per day usually controlled by rescue pain medication~* Able (or via caregiver)to evaluate and record pain relief, assess medication performance at set times after dosing, record adverse events, record each use of the study drug or rescue medication in a diary~* Able to be up and about for 50% of the day or greater~Exclusion Criteria:~* Intolerance to opioids or fentanyl~* rapidly increasing/uncontrolled pain~* pain that is not cancer related

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nasalfent, Fentanyl Citrate Nasal Spray (Type: EXPERIMENTAL): None
- Placebo Spray (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants that are 25 0/7 - 31 6/7 weeks gestation~* Infants who require Continuous Positive Airway Pressure (CPAP) or Positive Pressure Ventilation ( PPV) during delivery room resuscitation.~Exclusion Criteria:~* Refusal of consent~* Known complex congenital anomalies of the heart or lungs~* Known major genetic defects~* Hydrops fetalis

- Gender: ALL
- Minimum Age: 1 Minute
- Maximum Age: 2 Minutes
- Healthy Volunteers: f

Study Arms:
- Placebo 20ppm (Type: PLACEBO_COMPARATOR): Nitrogen at 20 ppm at the beginning of study start with gradual taper at 10 minutes of the study and completely off by 17 minutes of the study
- Inhaled Nitric Oxide (iNO) 20 ppm (Type: EXPERIMENTAL): Inhaled Nitric Oxide 20 ppm at the beginning of study start with gradual taper at 10 minutes of the study and completely off by 17 minutes of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ESRD patients~Exclusion Criteria:~* Diabetes Mellitus~* Severe and Malignant diseases~* Patients in Intensive Care Units

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 12 years of age or older with a minimum body weight of 40 kg~* Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate to severe disease (\>= the following scores: BSA 10%, IGA 3, EASI 16, Pruritus NRS 4)~* Recent history of inadequate response or inability to tolerate topical AD treatments or require systemic treatments for AD control~Exclusion Criteria:~* Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study~* Prior treatment with JAK inhibitors~* Other active nonAD inflammatory skin diseases or conditions affecting skin~* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator~* Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use contraception

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-04965842 100 mg (Type: EXPERIMENTAL): None
- PF-04965842 200 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Melatonin's Effect on Pain and Blood Loss After Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant women at term (37-40 wks) gestation scheduled for either elective or emergency lower segment cesarean section~Exclusion Criteria:~* women with any risk factor associated with an increased risk of postpartum hemorrhage were excluded i.e. multiple gestation, antepartum hemorrhage,poly-hydramnios, two or more previous cesarean sections and/or a history of previous rupture uterus~* current or previous history of significant disease including heart disease, liver, renal disorders ,anemia (Hb8 g%)or known coagulopathy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- melatonin 3mg (Type: ACTIVE_COMPARATOR): None
- melatonin 6mg (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Asthma with 15% or more increase in Forced expiratory volume at 1 second (FEV-1) after 180-360 mcg of albuterol pMDI~Exclusion Criteria:~* Any illness or condition which might place subject at risk in the study;e.g. some cardiovascular disorders Inability to understand and sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 / use of pMDI as approved (Type: OTHER): The intervention in this group will use inhalation from the pMDI containing budesonide/formoterol pMDI 160/4.5 2 inhalations as approved. (FDA approved product information) without a spacer. The pulmonary function tests (PFTs) will be collected at baseline and for a period of 12 hours post inhalation of 2 inhalation of budesonide /formoterol; pMDI160/5.
- Group 2 / pMDI with Aerochamber Plus (Type: EXPERIMENTAL): The intervention in this group will use the pMDI budesonide/formoterol 160/4.5 with a valve holding chamber spacer device, Aerochamber Plus which is the intervention being studied The PFTs will be collected at baseline and for a period of 12 hours post inhalation of 2 inhalation of Symbicort 160/5. This is the intervention to be studied for comparison to the non-spacer inhalations..

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who have been definitely diagnosed as leptomeningeal metastasis according to cerebrospinal fluid (CSF) cytology, or patients who got the clinical diagnosis by combining history of cancer, neuroimaging, clinical manifestation, and CSF examination, etc.~2. Patients who have been diagnosed as malignant solid tumor with definite pathologic type, excluding hematological malignancies (e.g., leukemia and lymphoma) or intracranial germ cell tumors;~3. No severe abnormal liver function; normal kidney function; WBC≥4000/mm3, Plt≥110000/mm3;~4. No other severe chronic diseases;~5. No severe dyscrasia.~Exclusion Criteria:~1. Patients with leptomeningeal metastasis from unknown primary tumor;~2. Patients who had received whole brain radiotherapy in the past 10 months;~3. Patients who had accepted systemic chemotherapy within two weeks, or molecular targeted therapy less than two weeks;~4. Patients with poor compliance, or for other reasons, the researchers considered unsuitable to participate in this clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group 1,Intra-pemetrexed, radiotherapy (Type: EXPERIMENTAL): The treatment regimen consisted of intrathecal chemotherapy (via lumbar puncture, pemetrexed 10 mg, plus dexamethasone 5 mg, once per week, 5-8 times, 4-7 weeks in total) and radiotherapy. Radiotherapy consisted of fractionated, conformal radiation given at a daily dose of 2 Gy. The planning volume consisted of sites of symptomatic disease, bulky disease observed on magnetic resonance imaging, including the whole brain and basis cranii received 40 Gy in 20 fractions, 4 weeks in total, and/or segment of spinal canal received 40-50 Gy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women at least 18 years of age at time of screening~* Chronic plaque-type psoriasis diagnosed for at least 6 months before randomization~* Moderate to severe psoriasis as defined at baseline by:~  * PASI score of 12 or greater~ * Investigator´s Global Assessment score of 3 or greater (based on a scale of 0 - 4) and,~ * Body Surface Area affected by plaque-type psoriasis of 10% or greater~* Chronic plaque-type psoriasis patients who have previously received phototherapy or systemic psoriasis therapy at least once or who are candidates for such therapies in the opinion of the investigator.~Exclusion Criteria:~* Forms of psoriasis other than chronic plaque-type~* Drug-induced psoriasis~* Ongoing use of prohibited psoriasis treatments~* Previous exposure to adalimumab~* Active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of treatment with adalimumab~Other In-/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GP2017 Adalimumab (Type: EXPERIMENTAL): Study arm with intervention being studied in the protocol. Adalimumab Solution for subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
- Humira ® Adalimumab (Type: ACTIVE_COMPARATOR): Humira® Adalimumab as a subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rehabilitation of the Upper Extremity With Enhanced Proprioceptive Feedback Following Incomplete Spinal Cord Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Traumatic SCI with tetraplegia.~* Male or female.~* 18-65 yrs old.~* At least 1 yr post-SCI.~* Tolerate sitting upright at for at least one hour.~* Able to perceive direction of passive joint(s) motion of the upper extremity(ies) to be treated 70% or more of the times tested.~* Motor grade \>1 in the wrist extensors, finger flexors and finger abductors (the 3 muscles related to hand movements in the ASIA scale) in the upper extremity tested.~* Cognitively and behaviorally capable of complying with the regimen.~Exclusion Criteria:~* Fracture of the treated limb resulting in loss of range of motion~* Concomitant TBI or stroke (Patients who sustained mild head injury during the trauma with no evidence of structural abnormalities on brain images will qualify for the study)~* DVT of the treated extremity~* Peripheral nerve injury of the treated extremity~* Osteo- or rheumatoid-arthritis limiting range of motion~* Contractures equal to or greater than 50% of the normal ROM~* Skin condition not tolerant of device~* Progressive neurodegenerative disorder~* Botox treatment of the treated extremity in the prior 5 month~* Chronic ITB therapy~* Uncontrolled seizure disorder~* Uncontrolled high blood pressure/angina~* Pain in affected limb or exercise intolerance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AMES treatment (Type: EXPERIMENTAL): The subject will receive 25 treatment sessions, conducted 2-3 times per week on the AMES device. Each session will consist of testing followed by 30 minutes of wrist and finger rehabilitation using the AMES device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete